Abstract
Cellular functions are controlled by genetic networks, and possible mutations in genes produce aberrations in normal cellular activity, disrupting the fine-tuning of genetic networks and resulting in disease or disorder. As a result, carrying out a systematic analysis of how diseases alter the character of these networks is critical. The analyzation of neurodegenerative and psychiatric diseases networks and the relevant information about signaling molecules, genes, and proteins, and their interactions, enable us to extract and display information related to the diseases in a variety of ways.
In this chapter, we will investigate the most common pathways of the diseases, the genes involved, the binding proteins that would possibly inform about the pathological cascade of the Parkinson, ALS, and Alzheimer neurodegeneration and the underlying patterns of genetics among patients with Schizophrenia. Precision medicine’s development, in combination with the diversity of biological and biomedical data sources and their diverse character, make integrating and exploring the information they contain more difficult. Translational research platforms and tools have been developed and introduced as a possible option in light of these multifactorial issues. Researchers in order to investigate integrated data for hypothesis generation and validation, as well as data exploration, have used corresponding tools and platforms.
Similar content being viewed by others
References
Alzheimer’s Disease Data Initiative. https://www.alzheimersdata.org/
Balendra R, Isaacs A (2018) C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14(9):544–558
Banci L, Bertini I, Boca M, Girotto S, Martinelli M, Valentine J, Vieru M (2008) SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization. PLoS ONE 3(2):e1677
Benatar M et al (2016) ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve 53(2):169–182
Bonafede R, Mariotti R (2017) ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles. Front Cell Neurosci 11
Bradshaw W, Rehman S, Pham T, Thiyagarajan N, Lee R, Subramanian V, Acharya K (2017) Structural insights into human angiogenin variants implicated in Parkinson’s disease and Amyotrophic Lateral Sclerosis. Sci Rep 7(1)
Cai L, Huang J (2018) Schizophrenia and risk of dementia: a meta-analysis study. Available via PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095111/. Accessed 20 Jan 2021
CellDesigner.: A modeling tool of biochemical network. http://www.celldesigner.org/
COPASI.: Biochemical System Simulator. http://copasi.org/
Deng Z, Lim J, Wang Q, Purtell K, Wu S, Palomo G, Tan H, Manfredi G, Zhao Y, Peng J, Hu B, Chen S, Yue Z (2019) ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy 16(5):917–931
DisGeNET. https://www.disgenet.org/home/
Dong Y, Chen Y (2018) The role of ubiquitinated TDP-43 in amyotrophic lateral sclerosis. Neuroimmunol Neuroinflamm 5(2):5
Elsevier’s Pathway Studio. https://www.pathwaystudio.com/
Fasana E, Fossati M, Ruggiano A, Brambillasca S, Hoogenraad C, Navone F, Francolini M, Borgese N (2009) A VAPB mutant linked to amyotrophic lateral sclerosis generates a novel form of organized smooth endoplasmic reticulum. FASEB J 24(5):1419–1430
Fecto F (2011) SQSTM mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68(11):1440
Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD et al (2018) GeneMANIA update 2018. Nucleic Acids Res 46:W60–W64
Ghasemi M, Brown RH Jr (2018) Genetics of amyotrophic lateral sclerosis. Cold Spring Harbor Persp Med 8(5):a024125. https://doi.org/10.1101/cshperspect.a024125
Gene Ontology (GO). http://geneontology.org/
GeneMANIA. http://genemania.org/
Grasso M, Piscopo P, Confaloni A, Denti M (2014) Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules 19(5):6891–6910
Guo J, Yang X, Gao L, Zang D (2017) Evaluating the levels of CSF and serum factors in ALS. Brain Behav 7(3):e00637
Healy D, Abou-Sleiman P, Gibson J, Ross O, Jain S, Gandhi S, Gosal D, Muqit M, Wood N, Lynch T (2004) PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63(8):1486–1488
Hedrich K, Winkler S, Hagenah J, Kabakci K, Kasten M, Schwinger E, Volkmann J, Pramstaller P, Kostic V, Vieregge P, Klein C (2006) RecurrentLRRK2 (Park8) mutations in early-onset Parkinson’s disease. Mov Disord 21(9):1506–1510
Horwitz T, Lam K, Chen Y, Xia Y, Liu C (2018) A decade in psychiatric GWAS research. Mol Psychiatry 24(3):378–389
Informatics for Integrating Biology and the Bedside – i2b2. https://community.i2b2.org/wiki/pages/viewpage.action?pageId=342684
Johnson J, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin V, Trojanowski J, Gibbs J, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez D, Arepalli S, Chong S, Schymick J, Rothstein J, Landi F, Wang Y, Calvo A, Mora G, Sabatelli M, Monsurrò M, Battistini S, Salvi F, Spataro R, Sola P, Borghero G, Galassi G, Scholz S, Taylor J, Restagno G, Chiò A, Traynor B (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68(5):857–864
KEGG DISEASE Database. https://www.genome.jp/kegg/disease/
KEGG NETWORK Database. https://www.genome.jp/network/nt06420+N01020
Koppers M, van Blitterswijk M, Vlam L, Rowicka P, van Vught P, Groen E, Spliet W, Engelen-Lee J, Schelhaas H, de Visser M, van der Kooi A, van der Pol W, Pasterkamp R, Veldink J, van den Berg L (2012) VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 33(4):837.e7–837.e13
Krüger R, Sharma M, Riess O, Gasser T, Van Broeckhoven C, Theuns J, Aasly J, Annesi G, Bentivoglio A, Brice A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson J, Hadjigeorgiou G, Hattori N, Ioannidis J, Jasinska-Myga B, Klein C, Lambert J, Lesage S, Lin J, Lynch T, Mellick G, de Nigris F, Opala G, Prigione A, Quattrone A, Ross O, Satake W, Silburn P, Tan E, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore D (2011) A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson’s disease. Neurobiol Aging 32(3):548.e9–548.e18
Lesage S, Brice A (2009) Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18(R1):R48–R59
Lev N, Roncevich D, Ickowicz D, Melamed E, Offen D (2006) Role of DJ-1 in Parkinson’s disease. J Mol Neurosci 29(3):215–226
Maere S, Heymans K, Kuiper M (2005) BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in biological networks. Bioinformatics 21:3448–3449
Martins M, Rosa A, Guedes L, Fonseca B, Gotovac K, Violante S, Mestre T, Coelho M, Rosa M, Martin E, Vance J, Outeiro T, Wang L, Borovecki F, Ferreira J, Oliveira S (2011) Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson’s disease. PLoS ONE 6(10):e25443
Miller D, O’Callaghan J (2015) Biomarkers of Parkinson’s disease: present and future. Metabolism 64(3):S40–S46
Ming F, Tan J, Qin L, Zhang H, Tang J, Tan X, Wang C (2020) The PARK2 mutation associated with Parkinson’s disease enhances the vulnerability of peripheral blood lymphocytes to paraquat. BioMed Res Int 2020:1–9
NeuroDNet. https://bioschool.iitd.ac.in/NeuroDNet/
Paré G, Leaver C, Bourget C (2018) Diffusion of the digital health self-tracking movement in Canada: results of a national survey. J Med Internet Res 20(5):e177. https://doi.org/10.2196/jmir.9388
Park J, Blair N, Sue C (2015) The role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms. Mov Disord 30(6):770–779
Parkinson N, Ince P, Smith M, Highley R, Skibinski G, Andersen P, Morrison K, Pall H, Hardiman O, Collinge J, Shaw P, Fisher E (2006) ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67(6):1074–1077
Renaud L, Picher-Martel V, Codron P, Julien J (2019) Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. Acta Neuropathologica Commun 7(1)
Sandstedt P, Littorin S, Johansson S, Gottberg K, Ytterberg C, Kierkegaard M (2018) Disability and contextual factors in patients with amyotrophic lateral sclerosis – a three-year observational study. J Neuromuscul Dis 5(4):439–449
Siddiqui I, Pervaiz N, Abbasi A (2016) The Parkinson disease gene SNCA: evolutionary and structural insights with pathological implication. Sci Rep 6(1)
STRING., Protein-Protein Interaction Networks – Functional Enrichment Analysis. https://string-db.org/
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C (2017) The STRING database in 2017: quality controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res 45(1):D362–D368. https://doi.org/10.1093/nar/gkw937
Tan L et al (2016) Toward precision medicine in neurological diseases. Ann Transl Med 4(6):104
The National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/
Toth R, Atkin J (2018) Dysfunction of optineurin in amyotrophic lateral sclerosis and glaucoma. Front Immunol 9
tranSMART. https://wiki.transmartfoundation.org/display/transmartwiki/tranSMART+Project+wiki+Home
UniProt. https://www.uniprot.org/
van Rooij E, Purcell A, Levin A (2012) Developing microRNA therapeutics. Circ Res 110(3):496–507
Vingill S, Brockelt D, Lancelin C, Tatenhorst L, Dontcheva G, Preisinger C, Schwedhelm-Domeyer N, Joseph S, Mitkovski M, Goebbels S, Nave K, Schulz J, Marquardt T, Lingor P, Stegmüller J (2016) Loss of FBXO 7 (PARK 15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice. EMBO J 35(18):2008–2025
Walker E, Kestler L, Bollini A, Hochman K (2004) Schizophrenia: etiology and course. Annu Rev Psychol 55(1):401–430
Wang L, Guo J, Zhang W, Xu Q, Zuo X, Shi C, Luo L, Liu J, Hu L, Hu Y, Yan X, Tang B (2011) Follow-up study of variants of the GIGYF2 gene in Chinese patients with Parkinson’s disease. J Clin Neurosci 18(12):1699–1701
Yoshino H, Tomiyama H, Tachibana N, Ogaki K, Li Y, Funayama M, Hashimoto T, Takashima S, Hattori N (2010) Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 75(15):1356–1361
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Kadena, K., Lazarou, E. (2022). Platforms for Analyzing Networks of Neurodegenerative and Psychiatric Diseases. In: Vlamos, P., Kotsireas, I.S., Tarnanas, I. (eds) Handbook of Computational Neurodegeneration. Springer, Cham. https://doi.org/10.1007/978-3-319-75479-6_5-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-75479-6_5-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-75479-6
Online ISBN: 978-3-319-75479-6
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences